Compare Las Vegas Sands Corp. (LVS) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs Recursion Pharmaceuticals Inc — how do they compare? Las Vegas Sands Corp. trades at $45.83 (market cap $29.44B), while Recursion Pharmaceuticals Inc trades at $3.38 (market cap $1.81B). The key difference: Las Vegas Sands Corp. is far larger — about 16.3× Recursion Pharmaceuticals Inc's market cap, and Las Vegas Sands Corp. pays a 2.64% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| LVS | RXRX | |
|---|---|---|
Market Cap | $29.44B | $1.81B |
Sector | Consumer Cyclical | Health |
52-Week High | $69.49 | $6.79 |
52-Week Low | $44.78 | $2.84 |
Enterprise Value | $41.33B | $1.33B |
Dividend Yield | 2.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LVS trades at $45.46, down 0.68% today, with a bearish technical signal from moving averages. The company reported mixed Q2 2026 earnings, missing EPS estimates at $0.59 versus $0.757 expected, but revenue growth remains robust with 2025 revenue at $13.02B. Analyst consensus is strongly bullish with a $60.75 price target and no sell ratings among 49 analysts. Recent news highlights corporate responsibility efforts and operational achievements in Macao.
The outlook is supported by strong fundamentals including a 12.59% net income margin and positive cash flow trends, but risks include high debt levels and competitive pressures. Upside potential exists if earnings rebound in Q3, aligning with analyst optimism, though technical weakness near support at $44 requires monitoring for stability.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
